Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Routine, nationwide molecular profiling of patients with advanced non-small cell lung cancer (NSCLC) is feasible and the screening detects actionable alterations that…
From - Diagnostic Testing & Emerging Technologies
There is universal recognition that genomic information has forever changed oncology care and is increasingly driving treatment decisions. For patients who have exhausted standard therapy or with…
From - Diagnostic Testing & Emerging Technologies
At-home testing company Cor (San Francisco) has taken to online crowdfunding to commercialize its blood chemistry device. As of April 6, the company had pledges on…
From - Diagnostic Testing & Emerging Technologies
The Targeted Agent and Profiling Utilization Registry (TAPUR) study began recruiting its first patients last month. The trial, the first clinical trial undertaken by …